Esculeogenin A
Esculeogenin A is the sapogenol of tomato saponin Esculeoside A (HY-N18067). Esculeogenin A is an orally active hepatoprotective, hypolipidemic, and antioxidant agent. Esculeogenin A regulates molecular targets like PPARα, SREBP1, Nrf2, NF-κB, ACAT1/ACAT2 to promote hepatic fatty acid oxidation, suppress de novo lipogenesis, enhance antioxidant defense, and inhibit inflammation. Esculeogenin A improves liver function, alleviates hyperlipidemia, and inhibits hepatic steatosis and foam cell formation, preventing nonalcoholic fatty liver disease in high-fat-diet-fed rats and reducing atherosclerotic lesions in apoE-deficient mice. Esculeogenin A can be used for the research of nonalcoholic fatty liver disease, atherosclerosis, and hyperlipidemia.
For research use only. We do not sell to patients.
- CAS No.: 854381-37-6
- Formula: C27H45NO4
- Molecular Weight:447.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
ACAT-1 |
ACAT-2 |
PPARα |
NF-κB |
In Vitro
Esculeogenin A (24 h) dose-dependently inhibits acetyl-LDL-induced cholesterol ester accumulation (but not triglyceride accumulation) in human monocyte-derived macrophages without inducing cytotoxicity[2].
Esculeogenin A (5 h) does not inhibit the association or degradation of acetyl-LDL in human monocyte-derived macrophages[2].
Esculeogenin A (24 h) dose-dependently inhibits cholesterol ester accumulation in Chinese hamster ovary cells overexpressing human ACAT-1 or human ACAT-2 without inducing cytotoxicity[2].
Esculeogenin A (15 min) dose-dependently inhibits ACAT activity in microsomes from human monocyte-derived macrophages, Chinese hamster ovary cells overexpressing human ACAT-1, and Chinese hamster ovary cells overexpressing human ACAT-2, with 50 μmol/L inhibiting HMDM ACAT activity by 40%[2].
Esculeogenin A (24 h) dose-dependently reduces ACAT-1 protein expression in human monocyte-derived macrophages without altering the expression of SR-A or SR-BI[2].
Esculeogenin A (10-100 μM; 24 h) potently inhibits cholesterol ester accumulation in human monocyte-derived macrophages (HMDMs) in a dose-dependent manner without affecting acetyl-LDL uptake or degradation, with 50 μM reducing accumulation by 40%[3].
Esculeogenin A (10-100 μM; 24 h) dose-dependently inhibits cholesterol ester accumulation in both hACAT-1 CHO cells and hACAT-2 CHO cells[3].
Esculeogenin A (10-100 μM) dose-dependently inhibits ACAT activity in human monocyte-derived macrophages (HMDMs), hACAT-1 CHO cells, and hACAT-2 CHO cells[3].
Esculeogenin A (10-50 μM; 24 h) dose-dependently reduces ACAT-1 protein expression in human monocyte-derived macrophages (HMDMs) without altering SR-A or SR-BI expression[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human monocyte-derived macrophages (HMDMs)
-
Concentration:10, 30, 50 μM
-
Incubation Time:24 h
-
Result:Reduced ACAT-1 protein expression in HMDMs in a dose-dependent manner.
Left SR-A and SR-BI protein expression unchanged relative to controls.
In Vivo
Esculeogenin A (100 mg/kg/day; p.o.; daily; 90 days), produced in vivo from orally administered Esculeoside A (HY-N18067), is detectable in the aortas of apoE-deficient mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (male, 10-11 weeks old, ~165 g initial weight, HFD-induced)[1]
-
Dosage:50 mg/kg; 100 mg/kg; 200 mg/kg
-
Administration:p.o.; daily; 12 weeks
-
Result:Dose-dependently reduced serum ALT, AST, GGT, serum/hepatic TGs, CHOL, LDL-c, liver weight/liver-to-body weight ratio, NF-κB nuclear activity, IKKβ activity, hepatic MDA, IL-6, TNF-α, and hepatic SREBP1, ACC mRNA.
Dose-dependently increased hepatic Nrf2 (mRNA, cytoplasmic, nuclear), GSH, SOD, CAT, HO-1, and hepatic PPARα, CPT I mRNA.
Dose-dependently reduced hepatocellular fat vacuoles and improved liver structure.
200 mg/kg reduced serum/hepatic TGs, CHOL, serum LDL-c in normal diet-fed rats, with no adverse effects on body weight, fat pad weight, or glucose/insulin parameters.
-
Animal Model:C57BL/6.KOR-Apoeshl (apoE-deficient)[2]
-
Dosage:50 mg/kg/day; 100 mg/kg/day (as esculeoside A, converted in vivo to esculeogenin A)
-
Administration:p.o.; daily; 90 days
-
Result:Reduced serum total cholesterol by approximately 25%, serum LDL cholesterol by approximately 25%, and serum triglycerides by approximately 45%.
Reduced total aortic surface atherosclerotic lesions to 8.2%.
Reduced aortic sinus cross-sectional lesion area by 52%.
Was detected in the aortas of treated mice, confirming in vivo conversion from Esculeoside A.
Chemical Information
-
CAS No. 854381-37-6
-
Molecular Weight 447.65
-
Formula C27H45NO4
-
SMILES
C[C@@H]1[C@@]2([C@@H](C[C@@H](CN2)CO)O)O[C@]3([H])[C@@]1([H])[C@@]4([C@@]([C@@]5([H])[C@]([C@@]6([C@@](C[C@H](CC6)O)([H])CC5)C)([H])CC4)([H])C3)C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Liver Histomorphometry
Liver histomorphometry is a quantitative histological approach used to measure structural alterations in hepatic tissue, including parenchymal loss, steatosis, fibrosis, and vascular remodeling, by combining stained tissue section analysis with stereological or computerized image-based measurements. Classical morphometric frameworks quantify volume fractions of liver compartments and fibrotic regions using systematic sampling and image analysis, enabling objective comparison of pathological changes across experimental groups. These approaches are widely applied in liver cirrhosis and fibrosis studies to reduce subjectivity in histological scoring and improve reproducibility of tissue evaluation. Recent methodological advances integrate automated image analysis and radiomics-based extraction of histological features from standard liver stains (e. g. , H&E and fibrotic stains), enabling quantitative correlation between morphometric features and fibrosis stages in non-alcoholic fatty live
Purity & Documentation
References
[1]. Al Jadani JM, et al. Esculeogenin A, a Glycan from Tomato, Alleviates Nonalcoholic Fatty Liver Disease in Rats through Hypolipidemic, Antioxidant, and Anti-Inflammatory Effects. Nutrients. 2023;15(22):4755. Published 2023 Nov 11. [Content Brief]
[2]. Zhang Y, et al. Effects of Treatment on Glucose Metabolism, Inflammation, Lipid Profile, and Atherosclerotic Lesions in db/db Mice. J Pharmacol Exp Ther. 2024; 380(2): 156-163. [Content Brief]
[3]. Nohara T, et al. The tomato saponin, esculeoside A. J Nat Prod. 2010;73(10):1734-1741. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Esculeogenin A
- 854381-37-6
- Drug Derivative
- Acyltransferase
- NF-κB
- PPAR
- Fatty Acid Synthase (FASN)
- Keap1-Nrf2
- nuclear factor kappa B kinase subunit beta
- human monocyte-derived macrophages
- apoE-deficient mice
- carnitine palmitoyltransferase I
- acetyl-CoA carboxylase
- nuclear factor erythroid 2-related factor 2
- nuclear factor-kappa beta
- Chinese hamster ovary cells
- peroxisome proliferator-activated receptor α
- sterol regulatory element-binding protein 1
- Inhibitor
- inhibitor
- inhibit